

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SciClone Pharmaceuticals (Holdings) Limited**

**賽生藥業控股有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6600)**

**UPDATE ON QUALIFICATIONS OF JOINT COMPANY SECRETARY  
AND RESIGNATION OF JOINT COMPANY SECRETARY**

Reference is made to the section headed “Waivers from strict compliance with the Listing Rules and exemptions from compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the prospectus of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”) dated February 19, 2021 in relation to, among other things, the appointment of Ms. Pan Rongrong (“**Ms. Pan**”) and Ms. Chan Sin Man Nico (“**Ms. Chan**”) as joint company secretaries of the Company and the waiver granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

The Company hereby announces that the Company has recently obtained a confirmation from the Stock Exchange that Ms. Pan has met the qualifications to act as company secretary of the Company as required under the Listing Rules such that a further waiver will not be necessary. Accordingly, Ms. Pan will act as the company secretary of the Company. Ms. Chan has resigned as the joint company secretary with effect from March 28, 2024.

Ms. Chan has confirmed that she has no disagreement with the Board and there is no matters relating to her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to take this opportunity to express its gratitude to Ms. Chan for her contribution to the Company during her tenure of service.

By Order of the Board  
**SciClone Pharmaceuticals (Holdings) Limited**  
**ZHAO Hong**  
*Executive Director, Chief Executive Officer and President*

Hong Kong, March 28, 2024

*As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.*

\* *for identification purpose only*